Orengo G, Noviello E, Cimoli G, Pagnan G, Parodi S, Venturini M, Conte P, Schenone F, Conzi G, Russo P
Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Jpn J Cancer Res. 1992 Nov;83(11):1132-6. doi: 10.1111/j.1349-7006.1992.tb02735.x.
Recombinant human tumor necrosis factor (rHuTNF) synergistically potentiates the cytotoxicity of the topoisomerase I inhibitor camptothecin, and the topoisomerase II inhibitors epidoxorubicin, etoposide, mitoxantrone, ellipticine, actinomycin D and 4'-(9-acridinylamino)methanesulfon-m-anisidide on A2780 human ovarian cancer cell line. Similar synergy was not observed with a combination of rHuTNF and cis-platinum or mitomycin C. When A2780 cells were incubated with rHuTNF simultaneously with camptothecin or mitoxantrone or VP16, increased numbers of DNA single-strand breaks were produced. rHuTNF alone did not induce DNA strand breakage. These data provide evidence that the enhancing effect of rHuTNF is closely related to the DNA damage mediated by topoisomerase-targeted drugs. These observations may have relevance for ovarian cancer treatment.
重组人肿瘤坏死因子(rHuTNF)可协同增强拓扑异构酶I抑制剂喜树碱、拓扑异构酶II抑制剂表柔比星、依托泊苷、米托蒽醌、椭圆玫瑰树碱、放线菌素D和4'-(9-吖啶基氨基)甲磺酰间茴香胺对A2780人卵巢癌细胞系的细胞毒性。rHuTNF与顺铂或丝裂霉素C联合使用时未观察到类似的协同作用。当A2780细胞与rHuTNF同时与喜树碱、米托蒽醌或VP16孵育时,会产生更多的DNA单链断裂。单独使用rHuTNF不会诱导DNA链断裂。这些数据证明rHuTNF的增强作用与拓扑异构酶靶向药物介导的DNA损伤密切相关。这些观察结果可能与卵巢癌治疗有关。